News / Insights

News & Blog

Regulatory updates. Practical perspectives.
A clearer view of what comes next.

Blog: Blog2

Why Your K-Clinic Launch Could Trigger an FDA "Drug Claim" — MoCRA Strategies for 2026

Exosomes, PDRN, and post-procedure care. These are the hottest keywords in the global beauty market today. As K-Beauty shifts its focus from "Glass Skin" to "Recovery and Regeneration," the so-called K-Clinic category is rapidly emerging. This is more than just a trend; consumers now expect professional, clinic-level results directly from their skincare products. However, the moment these expectations are translated into marketing copy, a significant risk arises in the U.S.

Everything About MoCRA

Provision Consulting Group

Mar 243 min read

Amazon Policy Pitfalls, Part 1: Prohibited Ingredients & New Rules You Can't Afford to Miss

An Amazon seller, let's call her A, once updated a single line on her cosmetic product label and suddenly her listing was deactivated. It...

FDA Regulations

Provision Consulting Group

Sep 26, 20253 min read

FDA Finalizes Mandatory Cosmetics Recall Guidance: What K-Beauty Brands Entering the U.S. Should Know

3 days ago

Renew Your FDA Initial Importer Designation with Provision

Oct 16

OTC Drug Establishment Renewal: Time to Renew with Provision

Oct 16

FDA Food Facility Registration: 2026 Is a Renewal Year

Oct 14

FY2027 FDA Medical Device Registration Renewal: It’s Time to Renew with Provision

Oct 14

FDA’s FY2027 Medical Device Guidance Agenda: What Could It Mean for 510(k) Manufacturers?

Oct 7

Provision CEO Sung Kwon to Speak at Cosmoprof Asia Hong Kong 2026

Oct 2

FDA’s Purolea Warning Letter: What AI-Assisted GMP Documentation Means for Manufacturers

Sep 23

FDA Form 483 Response Is Not the Finish Line: What the Bausch & Lomb Warning Letter Reveals About CAPA

Sep 19

FDA Sunscreen Regulatory Update: PABA and Trolamine Salicylate Removed from OTC Monograph M020

Sep 16

What Does It Mean When Torriden Delegates U.S. Regulatory Compliance to Provision Consulting Group?

Sep 9

Introducing the Provision Client Portal (Beta): A New Way to Work With Us

Sep 9

Why Provision Built R.I.S.E. Turning 50,000+ Real Regulatory Cases into Regulatory Intelligence

Aug 28

FY2027 FDA Medical Device User Fees Finalized: MDUFA V’s Final Year and What You Need to Know

Aug 24

Provision Consulting Group Speaks at ACI Conference on K-Beauty and U.S. Regulatory Challenges

Aug 18

MDUFA VI: Why FDA Device Reviews Are Getting Tougher, Not Faster

Aug 14

Trapped in Customs: The Hidden Triggers Behind FDA Import Alerts for Medical Devices

Aug 3

Container Stuck at a U.S. Port — What Triggers an FDA Import Alert for Food and Supplements

Jul 27

FDA US Agent: What Happens When They Go Silent — and You Picked Them on Price

Jul 20

What Huons' FDA Warning Letter Reveals About Today's CGMP Enforcement

Jun 30

FDA 510(k) Clearance: Why a "Complete" eSTAR Doesn’t Guarantee Approval

Jun 29

FDA Sunscreen Ingredient Update: Bemotrizinol Added to the U.S. OTC Monograph

Jun 23

A Kimchi Brand Just Got Recalled. The Culprit? Anchovies.

Jun 15

KOTRA x Provision Consulting Group to Support Korean Companies at BIO International Convention San Diego

Jun 11

The FDA is Cracking Down on Sunscreen Factories—Is Yours Truly Ready?

Jun 1

FDA-Compliant, Yet Still Sued? The Labeling Risks U.S.-Bound Brands Often Miss

May 15

Medical Devices Have IDs Too — The FDA UDI Guide for U.S. Market Entry

May 4

MoCRA Insight: Same Ingredients, Same Formula — Different FDA Interpretations

Apr 24

Longevity and In & Out Beauty: What K-Beauty Brands Are Missing in the U.S. Market

Apr 13

'Magnif's make p:rem', a K-Beauty Brand, Just Landed at Sephora. Here's What Made It Possible.

Mar 31

Why Your K-Clinic Launch Could Trigger an FDA "Drug Claim" — MoCRA Strategies for 2026

Mar 24

One Sunscreen Could Land You on FDA's Blacklist — Have You Checked Your OMUFA FY2026 Status?

Mar 13

Two More Digits. A Lot More Work. — FDA's NDC Format Change Explained

Mar 6

K-Beauty FDA Compliance: Why 'Marketing' Is No Longer Enough in the U.S. Market

Feb 24

[Cosmoprof Miami 2026] K-Beauty: Moving Beyond ‘Registration’ to ‘Regulatory Strategy’

Feb 16

The K-Beauty "Inner Beauty" Paradox: Why Your Best Marketing is Your Biggest Risk in the U.S.

Jan 30

2 3 4 5

From insight to action

What does this mean for your business?

Talk through your FDA questions with a team that stays close to the details.

Start a conversation ↗

REGULATORY SERVICES

MARKET ENTRY

News & Blog

Why Your K-Clinic Launch Could Trigger an FDA "Drug Claim" — MoCRA Strategies for 2026

Amazon Policy Pitfalls, Part 1: Prohibited Ingredients & New Rules You Can't Afford to Miss

FDA Finalizes Mandatory Cosmetics Recall Guidance: What K-Beauty Brands Entering the U.S. Should Know

Renew Your FDA Initial Importer Designation with Provision

OTC Drug Establishment Renewal: Time to Renew with Provision

FDA Food Facility Registration: 2026 Is a Renewal Year

FY2027 FDA Medical Device Registration Renewal: It’s Time to Renew with Provision

FDA’s FY2027 Medical Device Guidance Agenda: What Could It Mean for 510(k) Manufacturers?

Provision CEO Sung Kwon to Speak at Cosmoprof Asia Hong Kong 2026

FDA’s Purolea Warning Letter: What AI-Assisted GMP Documentation Means for Manufacturers

FDA Form 483 Response Is Not the Finish Line: What the Bausch & Lomb Warning Letter Reveals About CAPA

FDA Sunscreen Regulatory Update: PABA and Trolamine Salicylate Removed from OTC Monograph M020

What Does It Mean When Torriden Delegates U.S. Regulatory Compliance to Provision Consulting Group?

Introducing the Provision Client Portal (Beta): A New Way to Work With Us

Why Provision Built R.I.S.E. Turning 50,000+ Real Regulatory Cases into Regulatory Intelligence

FY2027 FDA Medical Device User Fees Finalized: MDUFA V’s Final Year and What You Need to Know

Provision Consulting Group Speaks at ACI Conference on K-Beauty and U.S. Regulatory Challenges

MDUFA VI: Why FDA Device Reviews Are Getting Tougher, Not Faster

Trapped in Customs: The Hidden Triggers Behind FDA Import Alerts for Medical Devices

Container Stuck at a U.S. Port — What Triggers an FDA Import Alert for Food and Supplements

FDA US Agent: What Happens When They Go Silent — and You Picked Them on Price

What Huons' FDA Warning Letter Reveals About Today's CGMP Enforcement

FDA 510(k) Clearance: Why a "Complete" eSTAR Doesn’t Guarantee Approval

FDA Sunscreen Ingredient Update: Bemotrizinol Added to the U.S. OTC Monograph

A Kimchi Brand Just Got Recalled. The Culprit? Anchovies.

KOTRA x Provision Consulting Group to Support Korean Companies at BIO International Convention San Diego

The FDA is Cracking Down on Sunscreen Factories—Is Yours Truly Ready?

FDA-Compliant, Yet Still Sued? The Labeling Risks U.S.-Bound Brands Often Miss

Medical Devices Have IDs Too — The FDA UDI Guide for U.S. Market Entry

MoCRA Insight: Same Ingredients, Same Formula — Different FDA Interpretations

Longevity and In & Out Beauty: What K-Beauty Brands Are Missing in the U.S. Market

'Magnif's make p:rem', a K-Beauty Brand, Just Landed at Sephora. Here's What Made It Possible.

Why Your K-Clinic Launch Could Trigger an FDA "Drug Claim" — MoCRA Strategies for 2026

One Sunscreen Could Land You on FDA's Blacklist — Have You Checked Your OMUFA FY2026 Status?

Two More Digits. A Lot More Work. — FDA's NDC Format Change Explained

K-Beauty FDA Compliance: Why 'Marketing' Is No Longer Enough in the U.S. Market

[Cosmoprof Miami 2026] K-Beauty: Moving Beyond ‘Registration’ to ‘Regulatory Strategy’

The K-Beauty "Inner Beauty" Paradox: Why Your Best Marketing is Your Biggest Risk in the U.S.

What does this mean for your business?